Phase II evaluation of bleomycin. A Southwest oncology Group study.

  title={Phase II evaluation of bleomycin. A Southwest oncology Group study.},
  author={Charles D. Haas and Charles Arthur Coltman and Jeffrey A. Gottlieb and A B Haut and Judith Luce and Robert W. Talley and Bohumil A. Samal and Helen E. Wilson and Barth Hoogstraten},
  volume={38 1},
Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less likely to casue pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were associated with a higher… CONTINUE READING

From This Paper

Topics from this paper.
13 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…